Enliven Therapeutics to Present Promising Data for ELVN-001 at EHA 2026 Congress

Exciting Developments in CML Treatment

Enliven Therapeutics, based in Boulder, Colorado, is capturing attention at the upcoming European Hematology Association (EHA) 2026 Congress. The event, scheduled for June 11-14 in Stockholm, Sweden, will highlight significant new data from their ongoing Phase 1 ENABLE clinical trial concerning the oral therapy ELVN-001, aimed at improving outcomes for patients with chronic myeloid leukemia (CML).

Overview of ELVN-001

ELVN-001 is a highly selective small molecule kinase inhibitor specifically designed to target the BCR-ABL1 gene fusion, an oncogenic driver critical for the progression of CML. This novel treatment shows promise as a best-in-class option for patients, especially those who have become resistant to existing therapies. In the ENABLE trial, participants include heavily pretreated patients with CML who have not responded to prior tyrosine kinase inhibitors (TKIs).

Trial Details and Efficacy Results

As of the last data cutoff on December 22, 2025, 141 patients were recruited for the ENABLE trial, with a median treatment period of approximately 32 weeks. Notably, the cumulative rate of achieving major molecular responses (MMR) was reported at 47%. Within a subgroup of patients who had previously received asciminib, the MMR rate rose to 52%, showcasing the treatment's effectiveness.

The data presented will encompass a broad range of patients treated under various dosing regimens, with the 80 mg once daily cohort having achieved remarkable results. In this cohort, 38% of participants saw their MMR status improve by week 24, indicating the potential for sustained therapeutic benefits.

Safety Profile

Most encouragingly, ELVN-001 maintained a favorable safety profile, with adverse reactions resulting in dosage reductions for fewer than 10% of patients and only 6.4% of participants discontinuing their treatment due to side effects. This tolerance is crucial for patients who often battle existing health complications from prior treatments.

Presentation Highlights

Dr. Dennis Kim will present the latest findings at the EHA Congress, slated for June 11 at 5:45 PM CEST. The presentation, titled ENABLE Updated Efficacy and Safety Results of ELVN-001, a Novel Selective ATP-Competitive Inhibitor of BCR-ABL1, in Patients with Previously Treated CP-CML, aims to share the breadth of efficacy and safety results, thus reinforcing the drug's potential impact on treatment paradigms for CML.

Conclusion

The anticipation surrounding ELVN-001 at the EHA Congress underlines its potential role in revolutionizing CML management. With continued exploration and validation in ongoing clinical trials, Enliven Therapeutics is taking significant steps toward addressing urgent unmet needs in oncology, offering hope for many patients.

For stakeholders in the medical community and interested parties, further details on the trial results will become available in the presentations section of Enliven’s website post-conference. This marks a pivotal moment for Enliven Therapeutics as they strive to bring forth innovative solutions for individuals battling CML.